Rivaroxaban is an oral anticoagulant that is the first available orally active direct Factor Xa inhibitor. In this study, a UV spectrophotometric method was developed for the determination of rivaroxaban content in pharmaceutical formulations and the amount of rivaroxaban released in tablet dissolution studies. The dissolution profile of rivaroxaban was successfully determined with the validated method.
No takes yet. Share an insight, caveat, or question.
Çelebi̇er et al. (2014) studied this question.
Synapse has enriched one closely related paper. Consider it for comparative context: